As the world’s third largest pharmaceutical market, Japan accounted for approximately 6% of the $1.5tn in global ...

Pfizer’s Braftovi (encorafenib) regimen has been granted accelerated approval by the US Food and Drug Administration (FDA) to ...

Merck & Co – known as MSD outside the US and Canada – will be gaining exclusive global rights to Hansoh Pharma’s preclinical ...

AI is shooting for the moon and the stars but the real benefits come from anchoring it to the human voice Research conducted ...

Elevate your MedEd strategy with our 2025 toolkit! From AI-driven patient avatars to interactive augmented reality scenarios, ...

Is your medical education strategy reaching the right HCPs in the formats they prefer? Discover actionable insights to ...

In theory, the principles of omnichannel – personalised content through the right channels to maximise customer experience – ...

Novo Nordisk has announced an investment of 8.5 billion Danish kroner, or approximately $1.2bn, to establish a new rare ...

If you are struggling to navigate the complexity of early commercialisation, rest assured, you are not alone. Clinical trial ...

At first glance, translating clinical outcome assessments (COAs) from their original language (most commonly English) to ...

And here lies the challenge for communicators: how do we effectively communicate an organisation’s approach to AI in a way ...

The results come two months after Merck shared positive results from the phase 3 KEYNOTE-689 trial of Keytruda as a ...